Lipoprotein(a): The Cardiovascular Risk Marker Everyone Will Test in 2026
By Dr. Sarah Mitchell, Respiratory Equipment Specialist & Wellness Editor · Published 2026-08-14 · 8 min read
One in five adults has elevated Lp(a). New siRNA drugs like pelacarsen and olpasiran are on track to lower it by 80%. Here is the 2026 screening and treatment update.
The Cholesterol Marker No One Told You About
Lipoprotein(a) is largely genetic, doesn't respond to diet or statins, and is a strong independent driver of premature heart attack, ischemic stroke, and aortic stenosis.
2026 Guideline Shift
ESC and ACC now recommend a one-time Lp(a) test for every adult. Levels >125 nmol/L multiply cardiovascular risk 2–4x.
Coming Therapies
- Pelacarsen — antisense oligonucleotide, phase 3 (HORIZON), ~80% Lp(a) reduction.
- Olpasiran / Zerlasiran — siRNA, quarterly injection.
- Muvalaplin — first oral Lp(a) inhibitor.
---
Round Out Your Home Health Setup
Pair the latest wellness protocols with clinical-grade monitoring. Browse portable oxygen concentrators, CPAP machines, and respiratory accessories — or call our respiratory therapists at (877) 699-4365 for a free consult.